Bone markers and osteoporosis therapy;Marcadores de turnover ósseo e tratamento da osteoporose

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 58, Issue 5, 2014, Pages 504-513

  Bandeira, Francisco ^a   Costa, Aline G ^b   Soares Filho, Manoel Aderson ^a   Pimentel, Larissa ^a   Lima, Lourena ^a   Bilezikian, John P ^b  

^a MINISTÉRIO DA SAÚDE   (Brazil)

^b Metabolic Bone Diseases Unit Division of Endocrinology Department of Medicine College of Physicians and Surgeons Columbia University ^*  (United States)

Author keywords

Bone density; Bone markers; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; COLLAGEN TYPE 1; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

BONE; BONE REMODELING; CLINICAL TRIAL (TOPIC); HUMAN; METABOLISM; OSTEOLYSIS; OSTEOPOROSIS; PHYSIOLOGY;

ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; BONE RESORPTION; CLINICAL TRIALS AS TOPIC; COLLAGEN TYPE I; DIPHOSPHONATES; HUMANS; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND;

EID: 84906702206     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/0004-2730000003384     Document Type: Review

References (57)

1. Datta HK, Ng W F, Walker JA, Tuck S P, Varanasi SS. The cell biology of bone metabolism. J Clin Pathol. 2008;61:577-587.
2. Carey JJ, Licata AA, Delaney M F. Biochemical markers of bone turnover. Clinic Rev Bone Miner Metab. 2006;4:197-212.
3. Vega D, Maalouf NM, Sakhaee K. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/ osteoprotegerin: clinical implications. J Clin Endocrinol Metab. 2007;92:4514-4521.
4. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann NY Acad Sci. 2008;1143:123-150.
5. National Institute for Health and Care Excellence 2014. Available at: www.guidance.nice.org.uk/TA160.
6. Khosla S, Melton LJ, 3rd, Riggs BL. The unitary model for estrogen defciency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res. 2011;26:441-451.
7. Wheater G, Elshahaly M, Tuck S P, Datta HK, van Laar JM. The clinical utility of bone marker measurements in osteoporosis. J Trans Med. 2013;11:201.
8. Lee J, Vasikaran S. Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Ann Lab Med. 2012;32:105-112.
9. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, et al.; Fracture Intervention Research Group. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res. 2006;21:292-299.
10. Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL; fracture intervention trial. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care. 2004;27:1547-1553.
11. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al.; Fracture Intervention Trial Study G. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004;19:1250-1258.
12. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Rise-dronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-1352.
13. Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, et al.; MOVER Study Group. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calc Tissue Int. 2013;93:137-146.
14. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al.; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
15. Reid IR, Brown J P, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661.
16. Reginster J Y, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocri-nol Metab. 2005;90:2816-2822.
17. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-468.
18. Chavassieux P, Meunier PJ, Roux J P, Portero-Muzy N, Pierre M, Chapurlat R. Bone histomorphometry of transiliac paired bone biopsies after 6 or 12 months of treatment with oral strontium ranelate in 387 osteoporotic women: randomized comparison to alendronate. J Bone Miner Res. 2014;29(3):618-628.
19. Bruyère O, Collette J, Rizzoli R, Decock C, Ortolani S, Cormier C, et al. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int. 2010;21:1031-1036.
20. Middleton E T, Steel SA, Aye M, Doherty SM. The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years. Osteoporos Int. 2012;23:295-303.
21. Sousa IO, Diniz E T, Marques T F, Griz L, Coutinho Mde A, Bandeira F. Short-term bone marker responses to teriparatide and strontium ranelate in patients with osteoporosis previously treated with bisphosphonates. Arq Bras Endocrinol Metab. 2010;54:244-249.
22. Lima H, Maia J, Bandeira F. Trajectories of bone remodeling markers and bone mineral density during treatment with strontium ranelate in postmenopausal women previously treated with bisphospho-nates. Clin Med Insights Endocrinol Diabetes. 2014;7:7-11.
23. Recker RR, Marin F, Ish-Shalom S, Möricke R, Hawkins F, Ka-petanos G, et al. Comparative effects of tereparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res. 2009;24:1358-1368.
24. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al.; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
25. Bone HG, Chapurlat R, Brandi ML, Brown J P, Czerwinski E, Krieg MA, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483-4492.
26. Nakamura Y. Evidence in the treatment of osteoporosis using weekly teriparatide injections. Clin Calcium. 2012;22:407-413.
27. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005;20:962-970.
28. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
29. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res. 2001;16:1846-1853.
30. Bilezikian J P. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep. 2008;6:24-30.
31. Lindsay R, Cosman F, Zhou H, Bostrom M P, Shen VW, Cruz JD, et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res. 2006;21:366-373.
32. Sugimoto T, Nakamura T, Nakamura Y, Isogai Y, Shiraki M. Profile of changes in bone turnover markers during once-weekly teripa-ratide administration for 24 weeks in postmenopausal women with osteoporosis. Osteoporos Int. 2014;25:1173-1180.
33. Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Effcacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab. 2012;97:3097-3106.
34. Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt DC, Rosen E, et al.; PTH Once-Weekly Research (POWR) Group. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Meatb. 2008;93:2166-2172.
35. Boonen S, Marin F, Obermayer-Pietsch B, Simões ME, Barker C, Glass EV, et al.; EUROFORS Investigators. Effects of previous an-tiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2008;93:852-860.
36. Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, et al; Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators. Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab. 2008;93:3785-3793.
37. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang T F, et al; PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmeno-pausal osteoporosis. N Engl J Med. 2003;349:1207-1215.
38. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349:1216-1226.
39. Deal C, Omizo M, Schwartz EN, Eriksen E F, Cantor P, Wang J, et al. Combination teriparatide and raloxifene therapy for post-menopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res. 2005;20:1905-1911.
40. Walker MD, Cusano NE, Sliney J Jr, Romano M, Zhang C, McMa-hon DJ, et al. Combination therapy with risedronate and teripara-tide in male osteoporosis. Endocrine. 2013;44:237-246.
41. Cosman F, Eriksen E F, Recknor C, Miller PD, Guañabens N, Kasperk C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2011;26:503-511.
42. Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382:50-56.
43. Leder B, Uihlein A, Tsai J, Neer R, Siwila-Sackman E, Zhu Y, et al. The DATA Extension Study: Two years of combined denosumab and teriparatide in postmenopausal women with osteoporosis: a randomized controlled trial. J Bone Miner Res. 2013;28 (Suppl 1); http://www.asbmr.org/education/AbstractDetail?aid=c6aff623-b458-4737-473 8c4733f-2381c4730a9217e
44. Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, et al. Two Years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014;99:1694-1700.
45. Krause C, Korchynskyi O, de Rooij K, Weidauer SE, de Gorter DJ, van Bezooijen RL, et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J Biol Chem. 2010;285:41614-41626.
46. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280:19883-19887.
47. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005;280:26770-26775.
48. van Bezooijen RL, Svensson J P, Eefting D, Visser A, van der Horst G, Karperien M, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res. 2007;22:19-28.
49. Van Buchem FS, Hadders HN, Ubbens R. An uncommon familial systemic disease of the skeleton: hyperostosis corticalis genera-lisata familiaris. Acta radiologica. 1955;44:109-120.
50. Truswell AS. Osteopetrosis with syndactyly; a morphological variant of Albers-Schonberg's disease. J Bone Joint Surg Br. 1958;40-B:209-218.
51. Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19-26.
52. Padhi D, Allison M, Kivitz AJ, Gutierrez MJ, Stouch B, Wang C, et al. Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol. 2013 Nov 23. doi: 10.1002/jcph.239. [Epub ahead of print]
53. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown J P, Diez-Perez A, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412-420.
54. Study of romosozumab (AMG 785) administered to healthy subjects and subjects with stage 4 renal impairment or stage 5 renal impairment requiring hemodialysis. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01833754?term=Romosozumab& rank=1. Acessed on Nov 20, 2013.
55. Study to determine the efficacy and safety of romosozumab in the treatment of postmenopausal women with osteoporosis. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01631214?term=Romosozumab& rank=5. Acessed on: Nov 20, 2013.
56. McColm J, Hu L, Womack T, Tang CC, Chiang AY. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res. 2014;29(4):935-943.
57. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian J P, Compston JE, Cummings SR, et al.; IOF CSA Inadequate Responders Working Group. Treatment failure in osteoporosis. Osteoporos Int. 2012;23:2769-2774.